These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6754219)

  • 1. [Clinical contribution to the study of indobufen, a new platelet aggregation inhibitor].
    Ciammaichella A; Luzi M; Pezzi F; Recchia O
    Clin Ter; 1982 Aug; 102(4):387-95. PubMed ID: 6754219
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of morning platelet aggregation in patients with ischemic cardiopathy after evening administration of indobufen].
    Craveri A; Lanfredini M; Citella C; Braconaro F; Colombo L
    Minerva Cardioangiol; 1988 Sep; 36(9):411-8. PubMed ID: 3226570
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term trial (6 months) of the platelet aggregation inhibitory activity and biological safety of indobufen in cerebrovascular patients.
    Mansi D; Majello L; Palma V; De Michele G; Buscaino GA
    Acta Neurol (Napoli); 1983 Dec; 5(6):447-55. PubMed ID: 6367383
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk].
    Di Blasi S; Pintacuda S; Ferotti N; Lo Coco L; Muratore A; Russo G; Di Blasi U; D'Alessandro M; Morici G; Fornaciari M
    G Clin Med; 1990 Dec; 71(12):727-31. PubMed ID: 2150826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet activity and tolerance of indobufen (K3920) in cerebrovascular disease: a therapeutic approach.
    Carrieri P; Orefice G; La Pia S; Indaco A; D'Acunio F; Iadevaia V
    Pharmatherapeutica; 1983; 3(6):410-6. PubMed ID: 6353432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.
    Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A
    Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
    Nenci GG; Berrettini M; Iadevaia V; Parise P; Ballatori E
    Pharmatherapeutica; 1982; 3(3):188-94. PubMed ID: 7134226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term antiplatelet activity and safety of indobufen in patients with cardiovascular disease. Italian Multicenter Study Group.
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):439-46. PubMed ID: 3899952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
    Vinazzer H; Fuccella LM
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of platelet aggregation in man by indobufen (K 3920).
    Vittoria A; Laghi Pasini F; Messa GL; Di Perri T; Corvi G; Fuccella LM
    J Int Med Res; 1981; 9(1):12-7. PubMed ID: 7202826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):783-96. PubMed ID: 94870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary studies on indobufen (K 3920). A new inhibitor of platelet aggregation.
    Gürsoy AZ; Yardimci TU; Emekli NB; Ugur MS; Ulutin ON
    Haematologica; 1981 Dec; 66(6):756-67. PubMed ID: 6802717
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of in vivo platelet aggregation by indobufen in angina patients during exercise.
    Pogliani EM; Fantasia R; Perini C; Corvi G
    J Int Med Res; 1981; 9(2):113-9. PubMed ID: 7014283
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of indobufen on leukocyte-dependent thrombocyte aggregation in patients with ischemic heart disease].
    Liusov VA; Diukov IV; Uteshev DV
    Kardiologiia; 1993; 33(4):22-3. PubMed ID: 7933785
    [No Abstract]   [Full Text] [Related]  

  • 15. [Critical study of the in vitro and in vivo effect of pyridinol carbamate on platelet adhesiveness and aggregation].
    Prost-Djovakovic RJ; Lecrubier C; Doumenc J; Samama M
    Therapie; 1975; 30(3):429-42. PubMed ID: 772874
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
    Bergamaschi M; Pierucci L; Branzoli U
    Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP).
    Visonà A; Davanzo S; Bruno R; Pagnan A
    J Int Med Res; 1983; 11(1):10-4. PubMed ID: 6832462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiaggregating effect of indobufen. Preliminary results of a study of 20 patients].
    Andriani A; Chiappetta MG; Mannarino E; Mosiello G; Zampa G; Beni A
    Recenti Prog Med; 1986 Dec; 77(12):580-6. PubMed ID: 3563087
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary human pharmacology studies on the inhibition of platelet aggregation by indobufen (K 3920).
    Pogliani E; Corvi G; Mandelli V; Fuccella LM
    Haematologica; 1981 Apr; 66(2):160-70. PubMed ID: 6115794
    [No Abstract]   [Full Text] [Related]  

  • 20. A prostacyclin-sparing effect of indobufen vs. aspirin.
    De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
    Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.